MedTrace Logo

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

NCT07289282 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-03-31

No results posted yet for this study

Summary

This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.

Conditions

  • Breast Cancer
  • Neoadjuvant Therapy
  • Pathological Response
  • Invasive Breast Carcinoma
  • MicroRNAs

Sponsors & Collaborators

  • Atlas University

    lead OTHER

Principal Investigators

  • Emine Yildirim, MD · Atlas University Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07289282 on ClinicalTrials.gov